• Cefiderocol Activity in Resistant European Isolates

  2026-09-17

  This European surveillance study directly compared cefiderocol with recent β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa and Acinetobacter spp., including meropenem-resistant isolates. Its large, phenotype-stratified design found consistently high cefiderocol susceptibility and linked resistance subsets to acquired β-lactamases and mutations in iron-uptake pathways, while also clarifying the limits of in vitro comparisons.

• Polybrene Workflows for Gene Delivery and Metabolic Studies

  2026-09-17

  Polybrene improves viral attachment and can strengthen lipid-mediated DNA delivery, making it useful for difficult-to-transfect cells. This guide connects those delivery workflows with experimental tests of the TCAIM–OGDH mitochondrial pathway while emphasizing controls, cytotoxicity checks, and practical optimization.

• Cholesterol for mRNA-LNP Research Workflows

  2026-09-16

  Learn how to use Cholesterol as a controlled formulation variable in mRNA lipid nanoparticles, membrane assays, and localized delivery studies. This workflow emphasizes solvent handling, comparative formulation design, assay controls, and troubleshooting rather than assuming that one lipid composition fits every application.

• High Viscosity, P-gp, and Cancer Chemoresistance

  2026-09-16

  The 2026 reference study identifies extracellular fluid viscosity as a mechanical regulator of doxorubicin resistance, connecting cytoskeletal remodeling and water influx to membrane tension, TRPV4–Ca2+ signaling, YAP activation, and P-gp upregulation. Its findings provide a mechanistic framework for studying how tumor physical properties influence ABC transporter-mediated drug resistance and for designing follow-up transporter experiments.

• SCH772984 HCl: ERK1/2 Inhibitor Workflows

  2026-09-15

  SCH772984 HCl provides a direct way to interrogate ERK1/2 activity in BRAF- and RAS-driven cancer models, from acute pathway pharmacology to long-term antiproliferative assays. This workflow also shows how to test, without overclaiming, whether ERK perturbation intersects with the APEX2–TERT biology reported in human embryonic stem cells and melanoma.

• Rucaparib (AG-014699) in DNA Damage Research

  2026-09-15

  Rucaparib, also called AG-014699 and PF-01367338, is a potent PARP1 inhibitor used in DNA damage response research. Its documented research profile includes PARP1 inhibition, persistent DNA-break markers, radiosensitization in defined prostate cancer models, and transporter-dependent disposition in mice.

• Digestive Transformations of Withania Bioactives

  2026-09-14

  The reference study integrates simulated gastrointestinal digestion with LC–MS/MS profiling, untargeted metabolomics, and molecular networking to determine how Withania somnifera leaf and root metabolites change before absorption. Its results distinguish labile compounds, including withaferin A and withanoside IV, from the comparatively stable withanolide A and show why botanical pharmacokinetic models must account for extract type and digestive transformation.

• CFDA SE Cell Tracer Kit: Practical Guide

  2026-09-14

  The CFDA SE Cell Tracer Kit supports stable fluorescent labeling for cell lineage tracing, cell proliferation studies, and in vitro or in vivo tracking workflows. It is appropriate when durable covalent marking is needed, but not for reversible labeling, short-term signal readouts, or immediate physiological measurements.

• Z-VEID-FMK for Reliable Caspase-6 Assays

  2026-09-13

  Learn how Z-VEID-FMK (SKU A1923) can support more interpretable apoptosis, viability, and caspase activity experiments. This scenario-driven guide covers mechanism, solvent compatibility, protocol design, cross-domain interpretation, and practical vendor-selection criteria.

• Octyl-α-ketoglutarate for HIF-1α Regulation

  2026-09-12

  Octyl-α-ketoglutarate provides a cell-permeable route to test whether α-ketoglutarate availability controls prolyl hydroxylase activity, HIF-1α stability, and metabolic phenotypes. This practical guide connects the reagent to IDH-driven colorectal cancer models, TCA cycle dysfunction research, and reproducible hypoxia assays.

• Cy3 NHS Ester (Non-Sulfonated): Practical Guide

  2026-09-11

  Cy3 NHS ester (non-sulfonated) provides orange fluorescence for amino-group labeling of proteins, peptides, and oligonucleotides when sensitive optical detection is required. It is best suited to workflows that can tolerate a DMSO, DMF, or ethanol co-solvent and is less suitable for delicate aqueous-only protein assays because the reagent is water-insoluble.

• KX2-391 Dihydrochloride: A Translational Playbook

  2026-09-11

  KX2-391 dihydrochloride, also known as Tirbanibulin dihydrochloride, illustrates how one small molecule can connect substrate-site Src inhibition, tubulin disruption, HBV transcriptional control, and emerging intracellular BoNT/A research. This thought-leadership guide translates the evidence into practical assay design, mechanism-aware interpretation, and a disciplined path from screening to translational decision-making.

• Early Life Adversity, Oxytocin, and Innate Defense

  2026-09-10

  This article in press identifies a superior colliculus oxytocin-signaling deficit as a mechanistic link between early life adversity and impaired looming-evoked innate defensive behavior in mice. The combination of developmental stress modeling, circuit analysis, receptor knockdown, and intranasal oxytocin rescue provides a framework for studying how early experience reshapes threat processing, while leaving important questions about generalizability and therapeutic translation.

• FAPα-Responsive Nanoparticles for Urinary Tumor Diagnosis

  2026-09-10

  Feng and colleagues developed magnetic iron oxide nanoparticles carrying a substrate–reporter peptide that is cleaved by fibroblast activation protein α in tumor tissue, releasing a detectable urinary signal. In an esophageal squamous cell carcinoma xenograft model, the platform combined tumor biodistribution imaging with urine ELISA and achieved an area under the ROC curve of 1.0, while remaining a preclinical diagnostic strategy rather than a validated clinical test.

• Baicalein Workflows for Cancer and Inflammation

  2026-09-09

  Build reproducible Baicalein assays around 12-LOX inhibition, apoptosis, inflammatory signaling, and cancer-cell phenotypes. This practical workflow also shows how to borrow assay logic from chemotherapy-neurotoxicity research without confusing evidence for formononetin with evidence for Baicalein.

7948 records 1/530 page Next 12345 下5页 Last page